Preferred Label : prostaglandins F;
MeSH definition : (9 alpha,11 alpha,13E,15S)-9,11,15-Trihydroxyprost-13-en-1-oic acid (PGF(1 alpha));
(5Z,9 alpha,11,alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (PGF(2
alpha)); (5Z,9 alpha,11 alpha,13E,15S,17Z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic
acid (PGF(3 alpha)). A family of prostaglandins that includes three of the six naturally
occurring prostaglandins. All naturally occurring PGF have an alpha configuration
at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are
often used as oxytocics.;
MeSH synonym : pgf;
CISMeF synonym : f, prostaglandins;
MeSH annotation : /biosyn /physiol permitted; /chem syn permitted: do not convert to PROSTAGLANDINS
F, SYNTHETIC; DF: PGF; /chem syn permitted: do not convert to PROSTAGLANDINS F, SYNTHETIC;
Wikipedia link : https://en.wikipedia.org/wiki/Prostaglandins f;
Is substance : O;
Origin ID : D011460;
UMLS CUI : C0033561;
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
Fils d'après SNOMED CT
Record concept(s)
Related MeSH Supplementary Concept(s)
Related MeSH term(s)
Semantic type(s)
UMLS correspondences (same concept)
(9 alpha,11 alpha,13E,15S)-9,11,15-Trihydroxyprost-13-en-1-oic acid (PGF(1 alpha));
(5Z,9 alpha,11,alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (PGF(2
alpha)); (5Z,9 alpha,11 alpha,13E,15S,17Z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic
acid (PGF(3 alpha)). A family of prostaglandins that includes three of the six naturally
occurring prostaglandins. All naturally occurring PGF have an alpha configuration
at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are
often used as oxytocics.
Summary Basis of Decision (SBD) for Saflutan
Tafluprost, 15 mcg/mL, solution, ophthalmic/topical
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00243
2014
false
true
false
Canada
French
English
summary of product characteristics
tafluprost
tafluprost
drug approval
canada
treatment outcome
clinical trials as topic
ophthalmic solutions
administration, ophthalmic
tafluprost
ocular hypertension
glaucoma, open-angle
risk assessment
drug evaluation
prostaglandins F
prostaglandins F
---
http://www.has-sante.fr/portail/jcms/c_1121543/saflutan-tafluprost-analogue-de-prostaglandine-en-collyre-synthese-d-avis
2011
France
French
evaluation of the transparency committee
guidelines for drug use
tafluprost
prostaglandins F
ophthalmic solutions
insurance, health, reimbursement
tafluprost
ocular hypertension
glaucoma, open-angle
treatment outcome
tafluprost
prostaglandins F
administration, ophthalmic
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-10/saflutan_-_ct-10571.pdf
http://www.has-sante.fr/portail/jcms/c_1100393/saflutan
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-11/saflutan_ct_10571.pdf
2011
France
French
English
evaluation of the transparency committee
tafluprost
tafluprost
insurance, health, reimbursement
ophthalmic solutions
glaucoma, open-angle
ocular hypertension
prostaglandins F
treatment outcome
tafluprost
instillation, drug
administration, ophthalmic
---